CVS Health Corporation $CVS Shares Sold by Cerity Partners LLC

Cerity Partners LLC trimmed its position in shares of CVS Health Corporation (NYSE:CVS) by 16.7% in the fourth quarter, HoldingsChannel reports. The firm owned 446,887 shares of the pharmacy operator’s stock after selling 89,609 shares during the period. Cerity Partners LLC’s holdings in CVS Health were worth $35,465,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the period. Ares Financial Consulting LLC acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $29,000. Dogwood Wealth Management LLC lifted its stake in shares of CVS Health by 93.7% in the 4th quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator’s stock worth $29,000 after acquiring an additional 179 shares during the period. GoalVest Advisory LLC acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $32,000. Finally, MidAtlantic Capital Management Inc. acquired a new stake in shares of CVS Health in the 4th quarter worth approximately $35,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Up 1.1%

NYSE CVS opened at $98.10 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The company’s 50 day simple moving average is $85.75 and its 200 day simple moving average is $80.47. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $98.61. The company has a market capitalization of $125.16 billion, a P/E ratio of 43.21, a PEG ratio of 0.95 and a beta of 0.62.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Thursday, April 23rd. CVS Health’s dividend payout ratio is 117.18%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research analyst reports. Barclays upped their price target on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. JPMorgan Chase & Co. upped their price target on shares of CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. UBS Group upped their price target on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. HSBC upped their price target on shares of CVS Health from $83.00 to $85.00 and gave the stock a “hold” rating in a research note on Tuesday, May 5th. Finally, DA Davidson boosted their target price on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, CVS Health currently has an average rating of “Moderate Buy” and an average price target of $100.68.

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. 0.85% of the stock is owned by insiders.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight management medications, which could improve access for members and support pharmacy benefit growth while reinforcing CVS’s role in a high-demand therapeutic category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options
• Positive Sentiment: Investor sentiment also improved after commentary that CVS is in a meaningful turnaround, with recent results showing stronger insurance performance and improving retail pharmacy market share. CVS Offers A Compelling Turnaround Opportunity Not Seen In Years
• Positive Sentiment: CVS was recognized for technology that improves medication safety and patient care, supporting the company’s long-term narrative around innovation and healthcare delivery efficiency. CVS Health Recognized for Technology That Improves Medication Safety and Patient Care
• Neutral Sentiment: CVS named Zach Dennett as interim merchandising leader after Musab Balbale departed the company, a leadership change that may draw attention but is not clearly material on its own. Musab Balbale Departs CVS Health; Zach Dennett Named Interim Merchandising Leader
• Neutral Sentiment: CVS also announced an AI Learning Academy for employees, underscoring ongoing investments in automation and workforce training, though the near-term stock impact is likely limited. CVS launched an AI Learning Academy for its workforce. Here’s why
• Negative Sentiment: Reports that major hospitals are suing CVS over an alleged drug discount scheme could raise legal and reputational risks, which may pressure the stock if the case gains traction. Major hospitals sue CVS over alleged drug discount scheme

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.